2006
SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells
Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene 2006, 25: 5180-5186. PMID: 16636677, DOI: 10.1038/sj.onc.1209520.Peer-Reviewed Original ResearchConceptsLymphoblastic leukemiaRecombinase activityRAG1/2 expressionB-cell lineage leukemiaDouble-strand break eventsLymphoma cellsSecondary genetic aberrationsB-cell lymphomaB-cell lymphoma cellsB-lymphoid malignanciesB-cell malignanciesB cell receptorVH gene rearrangementsMalignant progressionLeukemiaFrequent featureGenetic aberrationsGene rearrangementsCells resultsRearrangement activityLineage leukemiaMalignancyVH replacementDeficiencyExpression
2000
Defining CD95 as a tumor suppressor gene
Müschen M, Warskulat U, Beckmann M. Defining CD95 as a tumor suppressor gene. Journal Of Molecular Medicine 2000, 78: 312-325. PMID: 11001528, DOI: 10.1007/s001090000112.Peer-Reviewed Original ResearchConceptsTumor suppressor geneSuppressor geneCD95L expressionReceptor-ligand systemCD95L-mediated apoptosisKey regulatorDe novo expressionMalignant cellsGenesSomatic mutationsCD95 geneLymphocyte homeostasisBystander cellsCD95ApoptosisNatural ligandMalignant progressionNonmalignant counterpartsNovo expressionTumor progressionExpressionCellsTumor cellsGermlineAntitumor immunity